PPLPHARMA · Healthcare
Piramal Pharma Ltd. reported revenue of ₹1,959 cr for October to December 2023, — on the year and +2.5% on the quarter.
Operating profit (EBITDA) was ₹268 cr, a margin of 13.7%, — on the year and −22 bps on the quarter.
Net profit was ₹10.1 cr, — on the year and +102.2% on the quarter, with earnings per share of ₹0.08.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
Half or more of pre-tax profit came from other income. What is it, and does it repeat?
Other income was 223% of profit before tax.
Source: Quarterly statements
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,959 cr | ₹2,552 cr | ₹1,951 cr | ₹2,242 cr | ₹2,204 cr | ₹2,754 cr | ₹1,934 cr | ₹2,044 cr | ₹2,140 cr | ₹2,752 cr | ₹2,270 cr | ₹2,617 cr |
| YoY | — | — | +12% | +17% | +13% | +8% | −1% | −9% | −3% | −0% | +17% | +28% |
| EBITDA margin | 13.7% | 20.8% | 10.5% | 15.2% | 15.3% | 20.4% | 5.5% | 7.8% | 9.1% | 16.7% | 8.6% | 13.3% |
| Other income, % of PBT | 223% | 3% | — | 65% | 44% | 21% | — | — | — | −270% | — | 66% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 48% | 55% | — | — | — | 44% | — | — | — | — | — | — |
| Net profit | ₹10.1 cr | ₹101 cr | −₹88.6 cr | ₹22.6 cr | ₹3.7 cr | ₹154 cr | −₹81.7 cr | −₹99.2 cr | −₹136 cr | −₹8.8 cr | −₹69.4 cr | ₹5.0 cr |
| YoY | — | — | — | +352% | −64% | +52% | — | −539% | −3,801% | −106% | — | — |
| Core profit YoY | — | — | — | — | — | −2% | — | −403% | −382% | −26% | — | — |
| EPS | ₹0.08 | ₹0.77 | −₹0.67 | ₹0.17 | ₹0.03 | ₹1.16 | −₹0.61 | −₹0.75 | −₹1.02 | −₹0.07 | −₹0.52 | ₹0.04 |
| Flags | 1 | · | ✓ | 1 | ✓ | 1 | 1 | 2 | 2 | 2 | ✓ | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Piramal Pharma Ltd. reported revenue of ₹1,959 cr (— on the year) and net profit of ₹10.1 cr (— on the year) for October to December 2023.
1 check raised a question: Half or more of pre-tax profit came from other income. What is it, and does it repeat?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.